UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000028025
Receipt No. R000032090
Scientific Title Comparison between using PMMA and AN69ST membrane hemofilter in Continuous hemodiafiltration (CPAC study)
Date of disclosure of the study information 2017/07/01
Last modified on 2019/03/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Comparison between using PMMA and AN69ST membrane hemofilter in Continuous hemodiafiltration (CPAC study)
Acronym Comparison between using PMMA and AN69ST membrane hemofilter in Continuous hemodiafiltration (CPAC study)
Scientific Title Comparison between using PMMA and AN69ST membrane hemofilter in Continuous hemodiafiltration (CPAC study)
Scientific Title:Acronym Comparison between using PMMA and AN69ST membrane hemofilter in Continuous hemodiafiltration (CPAC study)
Region
Japan

Condition
Condition burn, severe acute pancreatitis, sepsis
Classification by specialty
Emergency medicine Intensive care medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To compare the clinical effects of continuous hemodiafiltration between using PMMA and AN69ST membrane hemofilter for the treatment of septic AKI.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes -Changes of scores (SOFA, SAPS2, APACHE2, DIC score, CAI) at 48 and 72 hours after enrollment
Key secondary outcomes -Duration of mechanical ventilation in 28 days
-Survival rate at 90 days
-ICU stay days
-Hospital stay days
-Changes of plasma lactate and IL-6 level at 72 hours after continuous hemodiafiltration
-Filter lifetime
-Total fluid volume

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Device,equipment
Interventions/Control_1 Continuous hemodiafiltration using PMMA membrane hemofilter
Interventions/Control_2 Continuous hemodiafiltration using AN69ST membrane hemofilter
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria ->=20 years of age
-Able and willing to provide informed consent
-Patients with burn, severe acute pancreatitis or sepsis
-Patients with KDIGO stage 1 screened
-Patients who require continuous hemodiafiltration for more than 24 hours
Key exclusion criteria -Pregnant women
-Patients with chronic kidney disease or who received RRT before randomization
-Patients with terminal cancer
-Patients with body weight less than 30 kg
-Patients considered ineligible for the study by the investigator
Target sample size 100

Research contact person
Name of lead principal investigator
1st name Ryota
Middle name
Last name Sakurai
Organization Faculty of Medicine, Saga University
Division name Department of Emergency and Critical Care Medicine
Zip code 849-8501
Address 5-1-1 Nabeshima, Saga City, Saga
TEL 0952-31-6511
Email sr0737@cc.saga-u.ac.jp

Public contact
Name of contact person
1st name Ryota
Middle name
Last name Sakurai
Organization Faculty of Medicine, Saga University
Division name Department of Emergency and Critical Care Medicine
Zip code 849-8501
Address 5-1-1 Nabeshima, Saga City, Saga
TEL 0952-31-6511
Homepage URL
Email sr0737@cc.saga-u.ac.jp

Sponsor
Institute Saga University
Institute
Department

Funding Source
Organization Toray Industries, Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Clinical research center, Saga University Hospital
Address 5-1-1 Nabeshima, Saga City, Saga
Tel 0952-34-3400
Email clinstudycenter@mail.admin.saga-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 佐賀大学医学部附属病院(佐賀県)、唐津赤十字病院(佐賀県)、独立行政法人国立病院機構 嬉野医療センター(佐賀県)、佐賀県医療センター好生館(佐賀県)

Other administrative information
Date of disclosure of the study information
2017 Year 07 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 05 Month 02 Day
Date of IRB
2016 Year 05 Month 02 Day
Anticipated trial start date
2017 Year 07 Month 01 Day
Last follow-up date
2019 Year 03 Month 20 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 06 Month 30 Day
Last modified on
2019 Year 03 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032090

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.